Importer of Controlled Substances Application: Globyz Pharma, LLC, 5920 [2023-01816]
Download as PDF
<![CDATA[
5920
Federal Register / Vol. 88, No. 19 / Monday, January 30, 2023 / Notices
lotter on DSK11XQN23PROD with NOTICES1
(March 19, 2020). Submissions should
refer to the investigation number (‘‘Inv.
No. 337–TA–1291’’) in a prominent
place on the cover page and/or the first
page. (See Handbook for Electronic
Filing Procedures, https://
www.usitc.gov/secretary/fed_reg_
notices/rules/handbook_on_electronic_
filing.pdf). Persons with questions
regarding filing should contact the
Secretary (202–205–2000).
Any person desiring to submit a
document to the Commission in
confidence must request confidential
treatment by marking each document
with a header indicating that the
document contains confidential
information. This marking will be
deemed to satisfy the request procedure
set forth in Rules 201.6(b) and
210.5(e)(2) (19 CFR 201.6(b) &
210.5(e)(2)). Documents for which
confidential treatment by the
Commission is properly sought will be
treated accordingly. A redacted nonconfidential version of the document
must also be filed simultaneously with
any confidential filing. All information,
including confidential business
information and documents for which
confidential treatment is properly
sought, submitted to the Commission for
purposes of this investigation may be
disclosed to and used: (i) by the
Commission, its employees and Offices,
and contract personnel (a) for
developing or maintaining the records
of this or a related proceeding, or (b) in
internal investigations, audits, reviews,
and evaluations relating to the
programs, personnel, and operations of
the Commission including under 5
U.S.C. Appendix 3; or (ii) by U.S.
government employees and contract
personnel, solely for cybersecurity
purposes. All contract personnel will
sign appropriate nondisclosure
agreements. All nonconfidential written
submissions will be available for public
inspection on EDIS.
This action is taken under the
authority of section 337 of the Tariff Act
of 1930, as amended (19 U.S.C. 1337),
and in Part 210 of the Commission’s
Rules of Practice and Procedure (19 CFR
part 210).
By order of the Commission.
Issued: January 25, 2023.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2023–01823 Filed 1–27–23; 8:45 am]
BILLING CODE 7020–02–P
VerDate Sep<11>2014
17:30 Jan 27, 2023
Jkt 259001
DEPARTMENT OF JUSTICE
Controlled substance
Drug
code
Schedule
1205
II
Drug Enforcement Administration
Lisdexamfetamine ..........
[Docket No. DEA–1139]
Importer of Controlled Substances
Application: Globyz Pharma, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Globyz Pharma, LLC. has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 1, 2023. Such
persons may also file a written request
for a hearing on the application on or
before March 1, 2023.
SUMMARY:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on December 30, 2022,
Globyz Pharma LLC, 7 Chelsea Parkway,
Suite 707, Boothwyn, Pennsylvania
19061–1300, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
ADDRESSES:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
The company plans to import the
listed controlled substance in dosage
form for use in a clinical trial. No other
activities for this drug code is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023–01816 Filed 1–27–23; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under The
Comprehensive Environmental
Response, Compensation, and Liability
Act (CERCLA), the Clean Water Act
(CWA), and the Oil Pollution Act (OPA)
On January 24, 2023, the Department
of Justice lodged a proposed consent
decree with the United States District
Court for the Western District of
Washington in the lawsuit entitled
United States of America, State of
Washington, Suquamish Tribe, and
Muckleshoot Indian Tribe v. Lynden,
Inc., et al., Civil Action No. 2:23–cv–
00101.
The proposed consent decree resolves
claims brought by the United States on
behalf of the National Oceanic and
Atmospheric Administration and the
Department of the Interior, the State of
Washington, the Suquamish Tribe, and
the Muckleshoot Indian Tribe
(collectively, the Natural Resource
Trustees) against Lynden, Inc., Knik
Construction Co., Inc., Douglas
Management Company, Alaska Marine
Lines, Inc., Swan Bay Holdings, Inc.,
Bering Marine Corp., 7100 First Avenue
S Seattle, LLC, 5615 West Marginal Way
SW Seattle, LLC, 5600 West Marginal
Way SW Seattle, LLC, LTI, Inc., Lynden
Transport, Inc. (f/k/a Lynden Transfer,
Inc.), and Alagnak Holdings, LLC
(Defendants) for natural resource
damages caused by releases of
hazardous substances and discharges of
oil from facilities owned and/or
operated at various times by the
Defendants, located along and near the
Lower Duwamish River, pursuant to
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 88, Number 19 (Monday, January 30, 2023)]
[Notices]
[Page 5920]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01816]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1139]
Importer of Controlled Substances Application: Globyz Pharma, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Globyz Pharma, LLC. has applied to be registered as an
importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
March 1, 2023. Such persons may also file a written request for a
hearing on the application on or before March 1, 2023.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on December 30, 2022, Globyz Pharma LLC, 7 Chelsea
Parkway, Suite 707, Boothwyn, Pennsylvania 19061-1300, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Lisdexamfetamine....................... 1205 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance in
dosage form for use in a clinical trial. No other activities for this
drug code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2023-01816 Filed 1-27-23; 8:45 am]
BILLING CODE 4410-09-P
